Lung Adenocarcinomas Manifesting As Radiological Part-Solid Nodules Define a Special Clinical Subtype.

Ting Ye,Lin Deng,Shengping Wang,Jiaqing Xiang,Yawei Zhang,Hong Hu,Yihua Sun,Yuan Li,Lei Shen,Li Xie,Wenchao Gu,Yue Zhao,Fangqiu Fu,Weijun Peng,Haiquan Chen
DOI: https://doi.org/10.1016/j.jtho.2018.12.030
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:Introduction: The clinicopathologic features and prognostic predictors of radiological part-solid lung adenocarcinomas were unclear. Methods: We retrospectively compared the clinicopathologic features and survival times of part-solid tumors with those of pure ground glass nodules (pGGNs) and pure solid tumors treated with surgery at Fudan University Shanghai Cancer Center and evaluated the prognostic implications of consolidation-to-tumor ratio (CTR), solid component size, and tumor size for part-solid lung adenocarcinomas. Results: A total of 911 patients and 988 pulmonary nodules (including 329 part-solid nodules [PSNs], 501 pGGNs, and 158 pure solid nodules) were analyzed. More female patients (p = 0.015) and nonsmokers (p = 0.003) were seen with PSNs than with pure solid nodules. The prevalence of lymphatic metastasis was lower in patients with PSNs than in those with pure solid tumors (2.2% versus 27% [p < 0.001]). The 5-year lung cancer-specific (LCS) recurrence-free survival and LCS overall survival of patients with PSNs were worse than those of patients with pGGNs (p < 0.001 and p = .042, respectively) but better than those of patients with pure solid tumors ([p < 0.001 and p < 0.0001, respectively]). CTR (OR = 12.90; 95% confidence interval [CI]: 1.85-90.04), solid component size (OR = 1.45; 95% CI: 1.28-1.64), and tumor size (OR = 1.23; 95% CI: 1.15-1.31) could predict pathologic invasive adenocarcinoma for patients with PSNs. None of them could predict the prognosis. Patients receiving sublobar resection had prognoses comparable to those of patients receiving lobectomy (p = .178 for 5-year LCS recurrence-free survival and p = .319 for 5-year LCS overall survival). The prognostic differences between patients with systemic lymph node dissection and those without systemic lymph node dissection were statistically insignificant. Conclusions: Part-solid lung adenocarcinoma showed clinicopathologic features different from those of pure solid tumor. CTR, solid component size, and tumor size could not predict the prognosis. Part-solid lung adenocarcinomas define one special clinical subtype. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?